The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance

BACKGROUND: Dysregulation of the canonical Wnt signaling pathway has been implicated in colorectal cancer (CRC) development as well as incipient stages of malignant transformation. In this study, we investigated the antitumor effects of AZ1366 (a novel tankyrase inhibitor) as a single agent and in c...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Quackenbush, Kevin S., Bagby, Stacey, Tai, Wai Meng, Messersmith, Wells A., Schreiber, Anna, Greene, Justin, Kim, Jihye, Wang, Guoliang, Purkey, Alicia, Pitts, Todd M., Nguyen, Anna, Gao, Dexiang, Blatchford, Patrick, Capasso, Anna, Schuller, Alwin G., Eckhardt, S. Gail, Arcaroli, John J.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5053726/
https://ncbi.nlm.nih.gov/pubmed/27070088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8626
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items